Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY – Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as $55.09 and last traded at $55.06, with a volume of 22902 shares. The stock had previously closed at $54.37.
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Stock Up 1.3 %
The stock has a fifty day moving average of $51.19 and a two-hundred day moving average of $49.15. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. The stock has a market cap of $75.14 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 0.69 and a beta of 1.02.
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (OTCMKTS:MURGY – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The financial services provider reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.07. The firm had revenue of $16.10 billion during the quarter. As a group, analysts predict that Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München will post 5.75 EPS for the current fiscal year.
About Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München engages in the insurance and reinsurance businesses worldwide. It also offers life and health reinsurance solutions, such as digital underwriting and advanced analytics solutions, health insurance management system, financial market risks, financing, portfolio risk management, digitalized investment-linked solution, MIRA digital suite, MIRA POS, MIRApply insured and physician, claims risk adjustment, CLARA plus, data analytics, underwriting and claims, medical research, capital management, and health market.
See Also
- Five stocks we like better than Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München
- The Role Economic Reports Play in a Successful Investment Strategy
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- 3 Small Caps With Big Return Potential
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Pros And Cons Of Monthly Dividend Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München and related companies with MarketBeat.com's FREE daily email newsletter.